Apelin

Wang, Ya Zhu; Fan, Jin‐Hu; Zhong, Bin; Xu, Qiang

doi:10.1097/md.0000000000012580

Cited by 9 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Встановлено, що рівень апеліну суттєво знижується вже на другу добу у пацієнтів з гострим інфарктом міокарда та у хворих на ішемічний інсульт. Слід зазначити, що рівень апеліну значно нижчий у курців в порівнянні з тими, хто немає цієї шкідливої звички [8,17,21] [3,14,20].…”

Section: вступunclassified

“…дослідження з певною долею ймовірності (відображено величиною отриманих ВШ) буде супроводжуватись зменшенням рівня апеліну-13 сироватки і навпаки -збільшення рівня пептиду сироватки буде призводити до зменшення величин ІЧ САТ, іЛП та середньої кількості ШЕ за 1 год. Це дозволяє думати про існування певних патофізіологічних зв'язків між рівнем апеліну-13, величинами АТ, ознаками перевантаження лівого передсердя, шлуночковою екстрасистолією та дисліпідемією, що ще раз доводить кардіопротекторний вплив апеліну-13 та знаходить підтвердження в ряді інших досліджень [3,5,11,15,20,22]. Позитивний LK з рівнем ЗХС свідчить про наявність прямого зв'язку між рівнем загального холестерину та рівнем апеліну-13 сироватки у хворих на ГХ ІІ стадії.…”

Section: обговоренняunclassified

See 1 more Smart Citation

Clinical and instrumental profile of patients with stage II essential hypertension with different forms of extrasystoles according to the level of apelin-13

Іvankova¹,

Kuzmіnova²,

Іванов³

2021

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. Essential hypertension (EH) is one of the leading causes of disability and mortality among cardiovascular diseases, so today new metabolic markers of cardiovascular risk are being actively studied. One of them is apelin-13. Objective – to evaluate the clinical and instrumental profile of patients with stage II hypertension with different forms of extrasystoles and different neurohumoral background – conditionally high/low serum apelin-13 levels. 156 patients with stage II essential hypertension were examined. 124 of them had frequent symptomatic extrasystoles, 32 patients had no arrhythmias and were considered to the comparison group. 30 practically healthy normotensive persons were considered to the control group. All patients underwent a complete clinical and anthropometric examination, blood pressure measurement, automatic daily blood pressure monitoring, daily electrocardiogram monitoring, echocardiography and the assessment of serum apelin-13 level. For statistical analysis, the procedure of non-linear data estimation was chosen, namely logistic regression or logit model. To form the basic statistical matrix of the analysis, we used clinical-instrumental and laboratory indicators, which passed a preliminary correlation analysis of Spearman with the level of apelin-13 serum and found a significant correlation (p<0.05). In the course of the logistic analysis at the final model, which allowed to predict “background of apelin” in patients with stage II EH entered 4 independent factors that revealed statistically significant (p<0.05) correlations with the initial parameter: the value of the systolic arterial pressure time index in%, the index of the left atrium in mm/m2, the average number of ventricular extrasystoles for 1 hour and the level of total cholesterol in plasma in mmol/l. The last indicator showed the least informativeness in predicting of the apelin-13 serum level. Interpreting the data of the obtained logit regression model, it should be said that in patients with EH of increasing the value of the systolic arterial pressure time index, the index of the left atrium and the average value of ventricular extrasystoles during 1 hour and decrease total cholesterol level in plasma increase the probability of determining relatively low (<920 pg/ml) and at the same time reduce the probability of determining a relatively high (≥920 pg/ml) level of apelin serum. These data also show that the highest informativeness in predicting the level of apelin-13 in patients with EH was the total number of ventricular extrasystole per hour. So, a high “apelin background” (≥920 pg/ml) in patients with EH will be accompanied by a benign course of the disease, so an increase serum apelin-13 in patients with EH should be considered as positive neurohumoral changes that promote cardioprotection, improve prognosis course of the disease and reduce cardiovascular risk.

show abstract

Section: вступunclassified

Section: обговоренняunclassified

Clinical and instrumental profile of patients with stage II essential hypertension with different forms of extrasystoles according to the level of apelin-13

Іvankova¹,

Kuzmіnova²,

Іванов³

2021

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

show abstract

“…However, peripheral blood apelin concentrations were not only significantly decreased in AF patients compared with healthy controls but also independently predicted recurrent AF in patients with persistent AF. This included cases occurring after pulmonary vein isolation in subjects without structural heart disease [170][171][172]. It has been suggested that low apelin levels may interfere with AF susceptibility through elevated atrial NADPH-dependent oxidative stress and the TGFβ/Smad2/α-SMA pathway associated with mitochondrial dysfunction and myocardial fibrosis [173,174].…”

Section: Apelinmentioning

confidence: 99%

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion

et al. 2023

View full text Add to dashboard Cite

Atrial fibrillation (AF) is associated with atrial remodeling, cardiac dysfunction, and poor clinical outcomes. External direct current electrical cardioversion is a well-developed urgent treatment strategy for patients presenting with recent-onset AF. However, there is a lack of accurate predictive serum biomarkers to identify the risks of AF relapse after electrical cardioversion. We reviewed the currently available data and interpreted the findings of several studies revealing biomarkers for crucial elements in the pathogenesis of AF and affecting cardiac remodeling, fibrosis, inflammation, endothelial dysfunction, oxidative stress, adipose tissue dysfunction, myopathy, and mitochondrial dysfunction. Although there is ample strong evidence that elevated levels of numerous biomarkers (such as natriuretic peptides, C-reactive protein, galectin-3, soluble suppressor tumorigenicity-2, fibroblast growth factor-23, turn-over collagen biomarkers, growth differential factor-15) are associated with AF occurrence, the data obtained in clinical studies seem to be controversial in terms of their predictive ability for post-cardioversion outcomes. Novel circulating biomarkers are needed to elucidate the modality of this approach compared with conventional predictive tools. Conclusions: Biomarker-based strategies for predicting events after AF treatment require extensive investigation in the future, especially in the presence of different gender and variable comorbidity profiles. Perhaps, a multiple biomarker approach exerts more utilization for patients with different forms of AF than single biomarker use.

show abstract

“…For example, in a series of 93 patients with persistent AF who underwent cardioversion, individuals with lower levels of apelin at baseline had a higher rate of AF recurrence at the 6-month follow-up [ 67 ]. Another series of 61 patients with AF who underwent pulmonary vein isolation showed that patients with lower serum levels of apelin at baseline had a higher rate of AF recurrence at 6 months post-procedure [ 68 ]. Interestingly, comparing 200 obese women to 200 lean women, Zaki et al found that obese women had a higher level of serum apelin compared to their lean counterparts [ 69 ].…”

Section: Mechanisms Underlying Obesity-related Afmentioning

confidence: 99%

Obesity-Related Atrial Fibrillation: Cardiac Manifestation of a Systemic Disease

Limpitikul,

Das

2023

JCDD

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with increased morbidity and mortality. The mechanisms underlying AF are complex and multifactorial. Although it is well known that obesity is a strong risk factor for AF, the mechanisms underlying obesity-related AF are not completely understood. Current evidence proposes that in addition to overall hemodynamic changes due to increased body weight, excess adiposity raises systemic inflammation and oxidative stress, which lead to adverse atrial remodeling. This remodeling includes atrial fibrosis, atrial dilation, decreased electrical conduction between atrial myocytes, and altered ionic currents, making atrial tissue more vulnerable to both the initiation and maintenance of AF. However, much remains to be learned about the mechanistic links between obesity and AF. This knowledge will power the development of novel diagnostic tools and treatment options that will help combat the rise of the global AF burden among the obesity epidemic.

show abstract

Apelin

Cited by 9 publications

References 43 publications

Clinical and instrumental profile of patients with stage II essential hypertension with different forms of extrasystoles according to the level of apelin-13

Clinical and instrumental profile of patients with stage II essential hypertension with different forms of extrasystoles according to the level of apelin-13

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion

Obesity-Related Atrial Fibrillation: Cardiac Manifestation of a Systemic Disease

Contact Info

Product

Resources

About